Crystal Arthropathies — Gout and Pseudogout Pathology

Gout Pathophysiology

• Hyperuricemia and MSU crystal formation: Elevated serum uric acid (>6.8 mg/dL, saturation point at physiologic pH and temperature) leads to precipitation of monosodium urate monohydrate crystals in synovial fluid. Uric acid is the end product of purine metabolism (xanthine oxidase catalyzes hypoxanthine → xanthine → uric acid). Crystal formation is favored by lower temperature (peripheral joints), lower pH (acidotic synovial fluid), lower synovial fluid volume, and presence of proteoglycans and other nucleating factors. Crystals preferentially deposit in joints with prior cartilage damage or osteoarthritis.

• NLRP3 inflammasome activation and acute inflammation: Needle-shaped MSU crystals are phagocytosed by macrophages and synovial lining cells, triggering NLRP3 inflammasome assembly (components: NLRP3 scaffold, ASC adaptor, pro-caspase-1). This leads to caspase-1 activation, which cleaves pro-IL-1β and pro-IL-18 to active forms. IL-1β is the primary driver of acute gouty arthritis—it upregulates COX-2 and prostaglandin production, increases vascular permeability, and orchestrates neutrophil chemotaxis via IL-8 and other chemokines. Crystal-induced release of danger-associated molecular patterns (DAMPs) such as cathepsin B (from phagolysosomal rupture) and adenosine triphosphate (ATP) amplifies inflammasome signaling.

• Resolution mechanisms and attack termination: Acute gout attacks spontaneously resolve despite continued MSU crystal presence. Resolution involves: (1) apolipoprotein B-100 coating of crystals, rendering them non-inflammatory; (2) production of anti-inflammatory mediators including TGF-β and IL-10; (3) recruitment and dominance of anti-inflammatory macrophages (M2 phenotype); and (4) exhaustion of neutrophil-derived IL-1β. Paradoxically, therapies that rapidly lower serum uric acid or mobilize tissue crystals can trigger acute attacks due to crystal shedding and inflammasome re-activation.

Pseudogout (CPPD) Pathophysiology

• CPPD crystal formation: Calcium pyrophosphate dihydrate crystals form in cartilage (chondrocalcinosis) through altered pyrophosphate metabolism. Pyrophosphate accumulates due to: (1) decreased activity of alkaline phosphatase (which normally hydrolyzes pyrophosphate), (2) increased activity of nucleotide pyrophosphatase/phosphodiesterase-1 (NPP1), or (3) genetic mutations (ANKH gene encodes an anion transporter promoting pyrophosphate efflux). Crystals are rhomboid or rod-shaped, positively birefringent, and deposit primarily in fibrocartilage and hyaline cartilage.

• NLRP3 inflammasome activation by CPPD: Like MSU crystals, CPPD crystals trigger NLRP3 inflammasome assembly and IL-1β production, though the mechanism involves different pattern-recognition receptors and the inflammation is typically milder and more chronic than in gout. CPPD arthropathy can present as acute pseudogout, chronic progressive arthritis mimicking osteoarthritis (most common presentation), or pseudorheumatoid arthritis with inflammatory polyarthritis.

Gout Etiologic Factors

• Hyperuricemia from increased production: Enzyme defects (HGPRT deficiency, PRPP synthetase overactivity), high purine diet (red meat, organ meats, seafood, high-fructose corn syrup), increased cell turnover (myeloproliferative disorders, psoriasis, hemolytic anemia, chemotherapy), and alcohol consumption (ethanol inhibits renal uric acid excretion and increases uric acid production).

• Hyperuricemia from decreased renal excretion: Most common cause of hyperuricemia (>90% of cases). Risk factors include chronic kidney disease, thiazide diuretics, loop diuretics, low-dose aspirin, cyclosporine, tacrolimus, and genetic variants in renal urate transporters (URAT1, GLUT9). Insulin resistance and metabolic syndrome increase serum uric acid through multiple mechanisms.

• Local joint factors promoting crystal deposition: Prior joint trauma or osteoarthritis, lower temperature in peripheral joints (first metatarsophalangeal joint classically affected due to distal location and repeated microtrauma), acidotic or hyperosmolar synovial fluid, and proteoglycans as nucleation sites.

• Additional risk factors: Male sex (4-5:1), age (peaks in 5th-6th decade for men; postmenopausal women), family history, obesity, hypertension, and diuretic use.

Pseudogout (CPPD) Etiologic Factors

• Metabolic disorders: Hyperparathyroidism (increases serum calcium and promotes CPPD deposition), hemochromatosis (iron deposition in cartilage alters pyrophosphate metabolism), hypomagnesemia, hypophosphatasia, hypothyroidism, and diabetes mellitus.

• Genetic predisposition: Mutations in ANKH gene (autosomal dominant familial CPPD arthropathy) and NPP1 gene alterations increase pyrophosphate levels.

• Age-related factors: CPPD prevalence increases dramatically with age (>80% of those >85 years may have chondrocalcinosis); reflects cumulative joint damage and altered metabolic regulation.

• Joint-specific factors: Prior osteoarthritis, meniscectomy, or other structural joint disease predisposes to CPPD deposition.

Acute Gouty Arthritis

• Sudden onset of monoarticular or oligoarticular arthritis: Typically affects lower extremities; first metatarsophalangeal joint (podagra) is pathognomonic (50% of first attacks). Pain reaches maximum intensity within 24-48 hours and is described as severe, throbbing, or unbearable. Patients often report nocturnal onset, possibly due to cooling of peripheral joints and relative dehydration during sleep.

• Physical examination findings: Swelling, erythema, warmth, and exquisite tenderness of affected joint(s). The overlying skin may appear shiny and tense. Fever (38-39°C) may accompany severe attacks. Movement of the joint is severely restricted due to pain. Tophi (deposits of monosodium urate crystals with surrounding fibrosis and chronic inflammation) appear as firm nodules on ears (helix), fingers, elbows, and other joints in chronic tophaceous gout. Tophi can ulcerate and drain chalky material rich in uric acid crystals.

• Associated systemic symptoms: Malaise, low-grade fever, elevated inflammatory markers (ESR, CRP), and leukocytosis with left shift on differential.

• Chronic tophaceous gout: Results from years of recurrent hyperuricemia and MSU deposition. Tophi are granulomatous lesions containing MSU crystals surrounded by epithelioid macrophages, giant cells, and fibrosis. Advanced tophaceous disease causes irreversible joint damage and erosions visible on radiography (punched-out erosions with overhanging edges).

Acute Pseudogout (Acute Chondrocalcinosis)

• Acute monoarticular or oligoarticular arthritis: Affects large joints more commonly than gout (knee > wrist > shoulder > ankle). Onset is acute but typically less severe than gout; attacks last 3-7 days if untreated (compared to 7-10 days for gout).

• Physical examination: Joint swelling, warmth, erythema, and tenderness; fever may be present but is usually lower grade than in gout. Joint motion is restricted.

• Chronic CPPD arthropathy: More common than acute pseudogout; presents insidiously with progressive joint pain, morning stiffness, and limited range of motion mimicking osteoarthritis. Polyarticular involvement (knees, wrists, MCPs, hips) occurs and can resemble rheumatoid arthritis clinically (pseudorheumatoid presentation). Chondrocalcinosis visible on radiographs.

Asymptomatic Chondrocalcinosis

• Incidental finding on imaging in older patients without clinical evidence of pseudogout; present in 5-10% of those >60 years and up to 30% of those >80 years.

Histological Findings

• Acute gouty arthritis synovial fluid: Negatively birefringent monosodium urate crystals (appear yellow when parallel to compensator, blue when perpendicular). Crystals are needle-shaped or rod-shaped with tapered ends, 2-8 micrometers in length. Crystals are intracellular (within neutrophils, macrophages, and synovial lining cells) and extracellular. Acute inflammation with predominance of polymorphonuclear leukocytes (neutrophils)—fluid contains 2,000-100,000 WBC/μL with >80% neutrophils during acute attack. Synovial fluid culture is negative (sterile inflammation).

• Chronic tophaceous gout histology: Monosodium urate crystal deposits surrounded by epithelioid macrophages, multinucleated giant cells, and lymphocytes forming a granuloma. Dense fibrosis encapsulates tophi. Tophi erode into surrounding bone and cartilage; erosions are characteristic with overhanging margins of intact bone at the erosion edge (pathognomonic finding on radiographs).

• Pseudogout synovial fluid: Positively birefringent calcium pyrophosphate dihydrate crystals (appear blue when parallel to compensator, yellow when perpendicular). Crystals are rhomboid or rod-shaped, smaller and more uniform than MSU crystals. Intracellular and extracellular distribution. Acute inflammation with predominance of neutrophils (though typically fewer than gout: 2,000-50,000 WBC/μL). Synovial fluid culture negative.

• Chronic CPPD arthropathy histology: Chondrocalcinosis with calcium pyrophosphate crystal deposits in cartilage matrix (fibroarticular cartilage and hyaline cartilage). Associated cartilage fibrillation, fragmentation, and loss mimicking osteoarthritis. Chronic inflammatory infiltrate with lymphocytes and macrophages. Synovial fibrosis.

Gross Pathology Appearance

• Acute gout: Synovial fluid appears turbid or purulent; frank pus-like appearance during severe attacks. Synovial membrane hyperemia and edema. Tophi appear as chalky, granular deposits in joints and surrounding tissues.

• Pseudogout: Less dramatic synovial inflammation than gout. Cartilage surfaces may show chalky deposits or a gritty appearance. Erosions and cartilage damage if chronic arthropathy present.

Laboratory Findings

• Serum uric acid: Elevated (>6.8 mg/dL) in gout, though notably may be normal during acute attack due to stress-induced decreases and consumption of urate. Should measure 2-4 weeks after attack resolution for accurate baseline.

• Synovial fluid analysis (diagnostic gold standard):
• Cell count: WBC 2,000-100,000/μL in acute gout; predominantly neutrophils (>80%).
• Crystal identification: Polarized light microscopy essential for diagnosis. MSU crystals are pathognomonic for gout; CPPD crystals diagnostic for pseudogout.
• Gram stain and culture: Negative (rules out septic arthritis, which can coexist with crystal arthritis).
• pH: Usually lower (acidotic) in gout.

• Serum inflammatory markers: Elevated ESR and CRP during acute attacks; help distinguish from other causes of monoarthritis.

• Complete blood count: Leukocytosis with left shift (elevated bands/immature forms) during acute attacks.

• Renal function and electrolytes: Assess baseline kidney function (important for management and prognosis). Check for hyperparathyroidism and other metabolic causes of CPPD.

Imaging Findings

• Plain radiographs in gout: Early attacks show soft tissue swelling only. Chronic tophaceous gout shows characteristic erosions with overhanging edges or "punched-out" appearance—erosions typically eccentric (off-center) on bone and associated with intact adjacent bone margin overhanging the defect. Tophi appear as soft tissue densities. Joint space narrowing and degenerative changes if secondary osteoarthritis develops.

• Plain radiographs in CPPD: Chondrocalcinosis—linear or stippled radiopaque deposits in cartilage, most commonly affecting knee menisci and articular cartilage, but also wrist fibrocartilage, symphysis pubis, and shoulders. Chronic arthropathy shows premature osteoarthritis-like changes: joint space narrowing, osteophytes, and subchondral sclerosis. Erosions less common than in chronic gout.

• Ultrasound: May show crystal deposits as hyperechoic collections and can aid in aspiration. "Double contour" sign (hyperechoic line along cartilage surface) seen in CPPD.

• CT/MRI: May show tophi, erosions, and crystal deposits but not routinely needed for diagnosis if synovial fluid analysis is available.

Diagnostic Criteria

• Gout: Diagnosis requires demonstration of needle-shaped, negatively birefringent monosodium urate crystals in synovial fluid obtained by arthrocentesis. Clinical presentation (acute monoarthritis with predisposing factors) plus imaging/labs supporting hyperuricemia are supportive but not diagnostic. Criteria exist (Rome criteria, ACR criteria) but crystal demonstration is definitive.

• Pseudogout: Diagnosis requires demonstration of rhomboid or rod-shaped, positively birefringent calcium pyrophosphate dihydrate crystals in synovial fluid. Associated imaging findings of chondrocalcinosis support diagnosis but are not required if crystals identified.

Acute Gouty Arthritis - First-Line Therapy

• NSAIDs (e.g., indomethacin 50 mg TID, naproxen 500 mg BID): Provide rapid anti-inflammatory effect by inhibiting prostaglandin synthesis and reducing IL-1β production downstream. Use highest tolerated dose initially, tapering over 1-2 weeks as inflammation resolves. Contraindicated in severe renal impairment, heart failure, or active GI bleeding. Onset of action 24-48 hours.

• Colchicine: Oral colchicine (1.2 mg loading dose, then 0.6 mg one hour later; then 0.6 mg daily for 7 days) inhibits NLRP3 inflammasome assembly, preventing IL-1β maturation and neutrophil recruitment. Most effective when started within 12-24 hours of symptom onset. GI side effects (diarrhea, nausea) are dose-limiting; monitor renal function closely. Avoid in severe kidney or hepatic disease. Alternative: low-dose colchicine 0.6 mg BID for 3-7 days.

• Corticosteroids: IL-1β inhibitors (canakinumab, anakinra) or oral/IM/intra-articular corticosteroids are alternatives for NSAID and colchicine contraindications. Oral prednisone 30-40 mg daily tapered over 7-10 days is effective

Disease-related complications

• Concomitant septic arthritis (emergency): MSU or CPPD crystals do not exclude infection — a damaged, crystal-laden joint is a nidus for bacterial seeding. Signals: synovial WBC in the tens of thousands with marked left shift, fever/rigors, or failure to defervesce on anti-inflammatory therapy. Every crystal aspirate needs Gram stain and culture; treat empirically pending results.
• Chronic tophaceous gout with joint destruction: persistent supersaturation drives granulomatous tophi that erode bone, producing punched-out erosions with overhanging edges, deformity, and nerve entrapment (carpal tunnel). Tophi may ulcerate and drain chalky material, with secondary bacterial superinfection.
• Urate renal disease: uric acid nephrolithiasis (radiolucent stones in acidic, concentrated urine) and chronic interstitial urate nephropathy. Acute uric acid nephropathy from tumor lysis syndrome is an emergency — oliguric AKI with markedly elevated uric acid after cytotoxic therapy.
• CPPD-specific complications: crowned dens syndrome — crystal deposition around the odontoid causing acute neck pain, fever, and elevated inflammatory markers that mimics meningitis or giant cell arteritis; also severely destructive "pseudo-neuropathic" arthropathy of the knee or shoulder.

Treatment-related complications

• Allopurinol hypersensitivity syndrome (emergency): DRESS or SJS/TEN with rash, eosinophilia, hepatitis, and AKI. The ACR 2020 gout guideline recommends *HLA-B\*58:01* testing before starting allopurinol in patients of Southeast Asian or African American ancestry.
• Xanthine oxidase inhibitor drug interactions: allopurinol blocks azathioprine/6-mercaptopurine catabolism → profound myelosuppression. Febuxostat carries an FDA boxed warning for cardiovascular death based on the CARES trial.
• Colchicine toxicity: CYP3A4/P-glycoprotein inhibitors (clarithromycin, cyclosporine) and renal impairment precipitate diarrhea, myelosuppression, and neuromyopathy with elevated CK.
• Pegloticase: anaphylaxis and infusion reactions; hemolysis and methemoglobinemia in G6PD deficiency — screen first.
• Mobilization flare: rapid urate lowering shifts tissue crystals into the joint, so ACR advises concurrent anti-inflammatory prophylaxis for months after initiating urate-lowering therapy.

• Single best next step in any acute monoarthritis: arthrocentesis with cell count, polarized light microscopy, and Gram stain/culture. Crystals never rule out infection — the two coexist, and missing septic arthritis is the tested error.
• Birefringence mnemonic: MSU is negatively birefringent, needle-shaped, and yellow when parallel to the compensator ("yell-par"); CPPD is positively birefringent, rhomboid, and blue when parallel. Intracellular crystals within neutrophils confirm an active crystal-driven attack.
• Serum uric acid is not a diagnostic test: it is frequently normal during an acute flare, so a normal level does not exclude gout, and asymptomatic hyperuricemia is not treated per the ACR 2020 gout guideline.
• Do not stop urate-lowering therapy during a flare: ACR 2020 permits initiating or continuing allopurinol during an attack as long as effective anti-inflammatory therapy is given concurrently. Stopping it is a classic distractor.
• The one association examiners test: chondrocalcinosis in a patient under roughly 55 years or in atypical joints mandates a workup for hemochromatosis, hyperparathyroidism, hypomagnesemia, and hypophosphatasia. CPPD in the second and third MCP joints with hook-like osteophytes is a hemochromatosis buzzword.
• Radiographic discriminator: gout gives eccentric erosions with overhanging edges and preserved joint space and bone density; rheumatoid arthritis gives marginal erosions with periarticular osteopenia and uniform joint space loss.
• Drug triggers to recognize in the stem: thiazide and loop diuretics, low-dose aspirin, cyclosporine/tacrolimus, and alcohol — all reduce renal urate excretion. Losartan is mildly uricosuric and is a reasonable antihypertensive choice in gout.
• Pathology-lab trap: urate crystals are water-soluble and dissolve in aqueous formalin, so a tophus must be fixed in absolute alcohol to preserve the needle-shaped crystals and surrounding foreign-body giant cell reaction.